Akèy › Kansè poumon selil ti › North Carolina
Etid klinik pou Kansè poumon selil ti nan North Carolina
16 etid pou Kansè poumon selil ti ap chèche patisipan nan sit nan North Carolina.
Vil nan North Carolina
Tèks ofisyèl etid la (Anglè)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Duke University, Durham
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Cape Fear Valley Cancer Center, Fayetteville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07472517A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- GSK Investigational Site, Wilson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07099898DESTINY-PANTUMOUR04
- Research Site, Durham
- Research Site, Wilson
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- FirstHealth of the Carolinas- Speciality Center /ID# 279857, Pinehurst
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07365241A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Duke Cancer Center Durham, Durham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07488676Study of Trilaciclib and Lurbinectidin
- Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05578326A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
- Duke Cancer Institute, Durham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07325136A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Duke Cancer Institute, Durham
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06646276A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Huntersville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07749586A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- University of North Carolina at Chapel Hill, Chapel Hill
- Duke University Medical Center, Durham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT05652686Tempus Small Cell Lung Cancer Observational Study (Sculptor)
- University of North Carolina, Chapel Hill
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 15, 2026 · NCT05257551Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
- FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Mar 30, 2026 · NCT06769126Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
- Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC, Salisbury
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Mar 11, 2026 · NCT06681220Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Carolina BioOncology Institute, Huntersville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Feb 18, 2026 · NCT07030257Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
- Lineberger Comprehensive Cancer Center, Chapel Hill
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Feb 5, 2026 · NCT05620342Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.